title: MOPP chemotherapy versus extended-field radiotherapy in the management of pathological stages I-IIA Hodgkin's disease.
abstract: In order to assess whether mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) chemotherapy (CT), which is less expensive and more easily available than radiotherapy (RT), is at least as effective as RT in terms of cure rate and has less iatrogenic damage, 89 consecutive patients with Hodgkin's disease (HD) (pathological stage I-IIA) were randomly allocated to receive mantle plus lumbar bar RT (36-45 Gy) or CT (six courses of MOPP). Forty-five patients were entered in the RT group and 44 in the CT group. The median follow-up was 60 months. Complete remission (CR) was obtained in all patients in the RT group and in 40 of 44 patients in the CT group. Overall survival (OS) and disease-free survival (DFS) were, respectively, 87.2% and 72.7% in the CT group and 93.5% and 74% in the RT group. Survival probability of relapsing patients was 76% for the patients in the RT group and 45% in the CT group. Treatment-related complications were more severe in the CT group as compared with the RT group.
authors.affiliation: Department of Human Biopathology, University La Sapienza, Rome, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Cimino
authors.forename: G P
authors.initials: GP
authors.lastname: Biti
authors.forename: A P
authors.initials: AP
authors.lastname: Anselmo
authors.forename: R
authors.initials: R
authors.lastname: Maurizi Enrici
authors.forename: G P
authors.initials: GP
authors.lastname: Bellesi
authors.forename: A
authors.initials: A
authors.lastname: Bosi
authors.forename: L
authors.initials: L
authors.lastname: Cionini
authors.forename: V
authors.initials: V
authors.lastname: Mungai
authors.forename: G
authors.initials: G
authors.lastname: Papa
authors.forename: P
authors.initials: P
authors.lastname: Ponticelli
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011344:Procarbazine / Q000008:administration & dosage / Q000009:adverse effects; D011897:Random Allocation; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone